APA Alıntı

Antonarakis, E. S., Tagawa, S. T., Galletti, G., Worroll, D., Ballman, K., Vanhuyse, M., . . . Giannakakou, P. (2017). Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. J Clin Oncol.

Chicago Stili Alıntı

Antonarakis, Emmanuel S., et al. "Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer." J Clin Oncol 2017.

MLA Alıntı

Antonarakis, Emmanuel S., et al. "Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer." J Clin Oncol 2017.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..